REPORT ID 4474

United States Live Attenuated Vaccine Market Report 2017

Publish Date
18-Dec-17
Pages
95
Format
Electronic (PDF)

In this report, the United States Live Attenuated Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Live Attenuated Vaccine in these regions, from 2012 to 2022 (forecast).

United States Live Attenuated Vaccine market competition by top manufacturers/players, with Live Attenuated Vaccine sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astellas Pharma (Japan)
    CSL Limited (Australia)
    Emergent BioSolutions (U.S.)
    GlaxoSmithKline (U.K.)
    Johnson & Johnson (U.S.)
    MedImmune (U.S.)
    Merck & Co (U.S.)
    Pfizer (U.S.)
    Sanofi Pasteur (France)
    Serum Institute of India Pvt (India)

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    By End User
        Pediatrics
        Adults
    By Disease Indication
        Pneumococcal
        Influenza
        HPV
        Hepatitis
        Rotavirus
        DTP
        Polio
        MMR
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Live Attenuated Vaccine Market Report 2017
1 Live Attenuated Vaccine Overview
    1.1 Product Overview and Scope of Live Attenuated Vaccine
    1.2 Classification of Live Attenuated Vaccine by Product Category
        1.2.1 United States Live Attenuated Vaccine Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Live Attenuated Vaccine Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Pediatrics
        1.2.4 Adults
    1.3 United States Live Attenuated Vaccine Market by Application/End Users
        1.3.1 United States Live Attenuated Vaccine Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Medical Center
        1.3.4 Others
    1.4 United States Live Attenuated Vaccine Market by Region
        1.4.1 United States Live Attenuated Vaccine Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.3 Southwest Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.5 New England Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.6 The South Live Attenuated Vaccine Status and Prospect (2012-2022)
        1.4.7 The Midwest Live Attenuated Vaccine Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Live Attenuated Vaccine (2012-2022)
        1.5.1 United States Live Attenuated Vaccine Sales and Growth Rate (2012-2022)
        1.5.2 United States Live Attenuated Vaccine Revenue and Growth Rate (2012-2022)

2 United States Live Attenuated Vaccine Market Competition by Players/Suppliers
    2.1 United States Live Attenuated Vaccine Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Live Attenuated Vaccine Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Live Attenuated Vaccine Average Price by Players/Suppliers (2012-2017)
    2.4 United States Live Attenuated Vaccine Market Competitive Situation and Trends
        2.4.1 United States Live Attenuated Vaccine Market Concentration Rate
        2.4.2 United States Live Attenuated Vaccine Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Live Attenuated Vaccine Manufacturing Base Distribution, Sales Area, Product Type

3 United States Live Attenuated Vaccine Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Live Attenuated Vaccine Sales and Market Share by Region (2012-2017)
    3.2 United States Live Attenuated Vaccine Revenue and Market Share by Region (2012-2017)
    3.3 United States Live Attenuated Vaccine Price by Region (2012-2017)

4 United States Live Attenuated Vaccine Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Live Attenuated Vaccine Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Live Attenuated Vaccine Revenue and Market Share by Type (2012-2017)
    4.3 United States Live Attenuated Vaccine Price by Type (2012-2017)
    4.4 United States Live Attenuated Vaccine Sales Growth Rate by Type (2012-2017)

5 United States Live Attenuated Vaccine Sales (Volume) by Application (2012-2017)
    5.1 United States Live Attenuated Vaccine Sales and Market Share by Application (2012-2017)
    5.2 United States Live Attenuated Vaccine Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Live Attenuated Vaccine Players/Suppliers Profiles and Sales Data
    6.1 Astellas Pharma (Japan)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Astellas Pharma (Japan) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 CSL Limited (Australia)
        6.2.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 CSL Limited (Australia) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Emergent BioSolutions (U.S.)
        6.3.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Emergent BioSolutions (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 GlaxoSmithKline (U.K.)
        6.4.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 GlaxoSmithKline (U.K.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Johnson & Johnson (U.S.)
        6.5.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Johnson & Johnson (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 MedImmune (U.S.)
        6.6.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 MedImmune (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Merck & Co (U.S.)
        6.7.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Merck & Co (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Pfizer (U.S.)
        6.8.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Pfizer (U.S.) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Sanofi Pasteur (France)
        6.9.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Sanofi Pasteur (France) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Serum Institute of India Pvt (India)
        6.10.2 Live Attenuated Vaccine Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Serum Institute of India Pvt (India) Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Live Attenuated Vaccine Manufacturing Cost Analysis
    7.1 Live Attenuated Vaccine Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Live Attenuated Vaccine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Live Attenuated Vaccine Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Live Attenuated Vaccine Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Live Attenuated Vaccine Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Live Attenuated Vaccine Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Live Attenuated Vaccine Sales Volume Forecast by Type (2017-2022)
    11.3 United States Live Attenuated Vaccine Sales Volume Forecast by Application (2017-2022)
    11.4 United States Live Attenuated Vaccine Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer